Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib for Relapsed/Refractory FLT3-ITD AML
NCT03622541Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Nov 2010
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in acute myeloid leukemia (AML), sponsored by The University of Hong Kong. Started Nov 2010; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03622541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622541.